drugset / Trial / NCT03905811

A Pilot Study of Terazosin for Parkinson's Disease

NCT03905811

Phase 1/2 Completed 13 enrolled Jordan Schultz University of Iowa · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.

Timeline

Start
2019-09-24
Primary completion
2020-06-05
Completion
2020-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Terazosin Small molecule 5 mg Oral

Indications